Community-acquired urinary tract infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in Zenica-Doboj Canton, Bosnia and Herzegovina

Medicinski Glasnik

Volumn 3, Issue 2, 2006, Pages 46-52

  Uzunovic Kamberovic, S ^a   Saric, D ^b   Sestic, S ^c  

^a Cantonal Public Health Institution Zenica   (Bosnia and Herzegovina)

^b Laboratory for Microbiology   (Bosnia and Herzegovina)

^c Cantonal Hospital   (Bosnia and Herzegovina)

Author keywords

Antibiotic susceptibility; E. coli; ESBL producers; K. Pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; EXTENDED SPECTRUM BETA LACTAMASE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BOSNIA AND HERZEGOVINA; COLIFORM BACTERIUM; CONTROLLED STUDY; ENTEROBACTERIACEAE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PREVALENCE; SPECIES DIFFERENCE; URINARY TRACT INFECTION;

EID: 33746388280     PISSN: 18400132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-780.
2. Cao V, Lambert T, Nhu DQ, Loan HK, Hoang NK, Arlet G, Courvalin P. Distribution of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002; 46: 3739-3743.
3. Bradford PA. Extended-spectrum beta-lactamase in the 21st century: characterization, epidemiology, and detection of this important resistance threat, Clin Microbiol Rev 2001; 14: 933-951.
4. Cormican M, Morris D, Corbett-Feeney G, Flynn J. Extended-spectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community-acquired urinary tract infection. Diagn Microbiol Infect Dis 1998; 32: 317-319.
5. Palucha A, Mikiewicz B, Hryniewicz W, Gniadkowski M. Concurrent outbreaks of extended-spectrum β-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J Antimicrob Chemother 1999; 44: 489-499.
6. Sorlózano A, Gutiérrez J, Palanca M, Soto MJ, Piédrola G. High incidence of extended-spectrum β-lactamases among outpatient clinical isolates of Escherichia coli: A phenotypic assessment of NCCLS guidelines and a commercial method. Diagn Microbiol Infect Dis 2004: 131-134.
7. Bou G, Cartelle M, Tomas M, Canle D, Molina F, Moure R, Eiros JM, Guerrero A. Identification and broad dissemination of the CTX-M-14 β-lactamase in different Escherichia coli strains in the Northwest area of Spain. J Clin Microbiol 2002; 40: 4030-4036.
8. Pournaras S, Ikonomidis A, Sofianou D, Tsakris A, Maniatis AN. CTX-M-type β-lactamases affect community Escherichia coli treatment, Greece. Emerg Infect Dis 2004; 10: 2004.
9. Bedenic B, Randegger CC, Stobberingh E, Hächler H. Molecular epidemiology of extended-spectrum β-lactamases from Klebsiella pneumoniae strains isolated n Zagreb, Croatia. Eur J Clin Infect Dis 2001; 20: 505-508.
10. Arpin C, Dubois V, Coulange L, André C, Fischer I, Noury P, Grobost F, Brochet J-F, Jullin J, Dutilh B, Larribet G, Lagrange I, Quentin C. Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003; 47: 3506-3514.
11. Kassis-Chikhani N, Vimont S, Asselat K, Trivalle C, Minassian B, Sengelin C, Gautier V, et al. CTX-M β-lactamase-producing Escherichia coli in long-term care facilities, France. Emerg Infect Dis 2004; 10: 1697-1698.
12. Bedenic B, Zagar Z. Extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae from Zagreb, Croatia. J Chemother 1998; 10: 449-459.
13. Rodríguez-Baño J, Navarro MD, Romero L, Martínez- Martínez L, Munianin MA, Perea EJ, Pérez-Cano R, Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
14. Wiener J, Quinn JP, Bradfroed PA, Goering RW, Nathan C, Bush K, Weinstein RA. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281; 281: 563-564.
15. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 2000; 19: 112-117.
16. Mirelis B, Navarro, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis 2003; 9: 1024-1025.
17. Uzunovic-Kamberovic S. Antibiotic resistance of coliform microorganisms from community-acquired urinary tract infections in the Zenica-Doboj Canton, Bosnia and Herzegovina. J Antimicrob Chemother (In press)
18. Yan JJ, Wu SM, Tsai SH, Wu JJ, Su IJ. Prevalence of SHV-12 among clinical isolates of K. pneumoniae producing extended-spectrum β-lactamases and identification of a novel AmpC enzyme (CMY-8) in Sothern Taiwan. Antimicrob Agents Chemother 2000; 44: 1438-1442.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. NCCLS document M100-S12. National Committee for Clinical Laboratory Standards, 2002, Wayne, Pa.
20. Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D, Couto E, Gutkind G, AND THE Microbiology Study Group. Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob Agents Chemother 2003; 47: 2864-2867.
21. Tzelepi E, Giakkoupi P, Sofianou D, Loukova V, Kemeroglou A, Tsakris A. Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol 2000; 38: 542-546.
22. Brown DF, Andrews J, King A, MacGowan AP and on behalf of the BSAC Sensitivity Testing Working Party. Detection of extended-spectrum β-lactamases with Etest and double-disc potentiation methods. J Antimicrob Chemother 2000; 46: 327-328.
23. Thomson K. Controversis about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001; 7: 333-336.
24. Gniadkowski FW, Multocentre study group. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBLproducing microorganisms. Clin Microbiol Infect 2001; 7: 597-608.
25. Sabaté M, Miró E, Navarro F, Vergés C, Aliaga R, Mirelis B, Prats G. β-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother 2002; 49: 989-997.
26. Manges AR, Johnson JR, Foxman B, O'Bryan TO, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001; 345: 1007-1013.
27. Rodrigues C, Shukla U, Jog S, Mehta A. Extended-spectrum β-lactamase-producing flora in healthy persons. Emerg Infect Dis 2005; 11: 981-982.
28. Kahlmeter G. The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000; 46 (Suppl A): 15-22.
29. Prais D, Straussberg R, Avitzur Y, Nussinovitch M, Harel L, Amir J. Bacterial susceptibility to oral antibiotics in community acquired urinary tract infections. Arch Dis Child 2003; 88: 215-218.
30. Gales AC, Jones RN, Gordon KA, Jones RN, Gordon KA, Sader HS, et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from second year of the SENTRY Antimicrobial Surveillance Program (1998). J Antimicrob Chemother 2000; 45: 295-303.
31. Barrett SP, Savage MA, Rebec MP, Guyot A, Andrews N, Shrimpton SB. Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infections in Britain. J Antimicrob Chemother 1999; 44: 359-365.
32. Aspevall O, Hallander H, Gant V, Kouri T. European guidelines for urinalysis: collaborative document produces by European clinical microbiologists and clinical chemists under ECLM in collaboration with ESCMID. Clin Microbiol Infect 2001; 7: 173-178.
33. Oteo J, Aracil B, Hoyo JF, Perianes J, Gomez-Garcés JL, Alós JI. Do the quinolones still constitute valid empirical therapy for community-acquired urinary tract infections in Spain. Clin Microbiol Infect 1999; 5: 654-646.
34. Samaha-Kfoury JN, Araj GF. Recent developments in β-lactamases and extended spectrum β-lactamases. BMJ 2003; 327: 1209-1213.
35. Thomson KS, Sanders CC. A simple and reliable method to screen isolates of Escherichia coli and Klebsiella pneumoniae for the production of TEM- and SHV-derived extended-spectrum β-lactamase. Clin Microbiol Infect 1997; 3: 549-554.